Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | CKS1B | P61024 | 1/20 | 0.55 |
| ▸ | SKP1 | P63208 | 1/20 | 0.55 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13703137 | 1.00 | JAK3 (0.56) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL13703442 | 1.00 | JAK3 (0.56) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL23497780 | 0.93 | BTK (0.64) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL29932659 | 0.93 | BTK (0.64) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL30665075 | 0.86 | JAK3 (0.52) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL24817207 | 0.86 | JAK3 (0.52) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL18228085 | 0.85 | GPR119 (0.58) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL18228358 | 0.85 | GPR119 (0.58) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL529863 | 0.84 | MAP4K4 (0.58) | JAK3BTKCKS1BSKP1SKP2 | |
| SCHEMBL594137 | 0.84 | MAP4K4 (0.58) | JAK3BTKCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-09-03 | — | — | US | disclosed |
| WO-2007081897-A2 | FUSED TRIAZOLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221611-A1 | Fused Triazole Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | JAK3 1097/4885BTK 4490/4885CKS1B 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.